



Neuren Pharmaceuticals Limited
Level 2, 57 Wellington Street
Freemans Bay, Auckland, New Zealand
office: +64 9 529 3940
fax: +64 9 361 7981
enquiries@neurenpharma.com
www.neurenpharma.com

10 July 2009

The Company Announcements Office
ASX Limited

Neuren Pharmaceuticals Limited Share Purchase Plan

On 1 July 2009 Neuren Pharmaceuticals Limited (Neuren or the Company) announced that it would make another offer under its Share Purchase Plan (SPP) to shareholders. In compliance with ASX Listing Rules, Neuren provides the following information:

1. Neuren is offering each shareholder with a registered address in Australia or New Zealand a minimum of A\$900 and a maximum of A\$10,000 worth of new fully paid ordinary shares in the capital of the Company at a price of A\$0.03 per share.
2. The SPP will be available to Australian and New Zealand shareholders who purchase shares on or before 13 July 2009 and are registered shareholders at 7.00pm (AEST) on 16 July 2009 (the Record Date).
3. The maximum number of shares which may be issued (without shareholder approval) is 77,239,293. Given the number of shareholders in Australia and New Zealand this SPP offer may be over-subscribed in which case the Company reserves the right to scale back acceptances or seek shareholder approval to issue a greater number of new fully paid ordinary shares.
4. Custodians acting as trustee or nominee in respect of more than one beneficiary will be able to apply for up to A\$10,000 of new shares for each different beneficiary provided they give the certification and details of each beneficiary required by the Australian Securities and Investments Commission (ASIC) Class Order CO 09/425.
5. The new shares will on allotment rank equally with existing ordinary shares on issue.
6. The Company is able to make this offer to Australian shareholders without providing a disclosure document in accordance with class order relief provided by ASIC and the New Zealand Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2009. A waiver has been sought from ASX regarding the recent increase in maximum subscription amount per annum by ASIC which exceeds the relevant Listing Rule exception. As noted above, should this SPP offer be over-subscribed the Company reserves the right to seek shareholder approval pursuant to ASX Listing Rule 7.1 for all or a part of the oversubscribed shares to be issued in the SPP.
7. The letter to shareholders setting out the terms of the SPP will be mailed to shareholders on 20 July 2009.

8. The purposes of the SPP are to give shareholders the opportunity to subscribe for shares at a discounted share price of A\$0.03 per share without having to incur brokerage fees, and to raise additional funds for the Company to meet working capital requirements.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Rob Turnbull', written in a cursive style.

Mr Rob Turnbull
Chief Financial Officer